Skip to main content

Table 1 Baseline characteristics of the participants

From: A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis

Characteristic TLHS 4.8 g TLHS 3.6 g TLHS 2.4 g Placebo
Age, years, mean ± SD 47.54 ± 11.14 50.76 ± 9.69 50.59 ± 10.61 50.12 ± 10.45
Gender, n, M : F 12:47 11:48 8:51 7:52
Height, cm, mean ± SD 162.88 ± 6.49 162.08 ± 6.16 161.78 ± 5.40 162.37 ± 5.60
Weight, kg, mean ± SD 61.83 ± 9.87 61.04 ± 9.65 60.14 ± 9.04 61.88 ± 9.29
Marital status, married : other 53:6 56:3 55:4 56:3
Duration of disease, months 3.00–180.00 2.00–216.00 5.00–183.00 2.00–276.00
Medication, use : no use 20:39 28:31 32:27 28:31
Radiographic stage, I : II : III 30:25:4 23:32:4 27:22:10* 33:21:5
Joint functional stage, I : II : III 13:46:0 9:47:3 9:42:8 15:40:4
Pain (VAS), cm, mean ± SD 5.68 ± 1.12 5.68 ± 1.27 5.48 ± 1.19 5.52 ± 1.13
Tender joint counts, n, mean ± SD 9.12 ± 5.07 8.47 ± 5.06 7.36 ± 3.87 9.24 ± 5.33
Swollen joint counts, n, mean ± SD 6.27 ± 3.47 5.83 ± 3.34 5.20 ± 2.54 6.19 ± 3.57
Morning stiffness, min, mean ± SD 82.03 ± 37.73 81.36 ± 37.61 83.31 ± 50.88 90.25 ± 71.24
Grip strength, mmHg, mean ± SD 36.11 ± 25.84 32.53 ± 22.57 35.07 ± 24.00 34.87 ± 24.97
Physician’s assessments, score, mean ± SD 5.32 ± 1.12 5.34 ± 1.33 5.07 ± 1.11 5.30 ± 1.17
HAQ, score, mean ± SD 16.68 ± 11.87 18.10 ± 12.78 15.39 ± 11.09 17.07 ± 12.85
RF, U/ml, mean ± SD 163.69 ± 258.04 74.72 ± 110.88 99.19 ± 149.96 79.04 ± 131.09
CRP, mg/dl, mean ± SD 7.38 ± 15.13 11.11 ± 30.01 6.83 ± 12.42 7.49 ± 16.67
ESR, mm/h, mean ± SD 22.39 ± 19.73 27.21 ± 25.14 27.93 ± 25.00 26.39 ± 23.04
  1. *P < 0.05 versus the placebo group
  2. VAS visual analog scale, HAQ Health Assessment Questionnaire, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate